DEC 23, 2019 8:40 AM PST

Novel Drug for Treating Insomnia

WRITTEN BY: Nouran Amin

The U.S. Food and Drug Administration (FDA) has approved DAYVIGO™ (lemborexant) in 5 mg and 10 mg for the treatment of insomnia among adult patients with insomnia. Insomnia is a difficult sleeping condition characterized by the inability to sleep or maintain sleep.

Learn more about insomnia:

Approval for DAYVIGO comes after two randomized and double-blined Phase 3 studies that evaluated the efficacy of the drug in comparison to the placebo. One study noted results for one month and the other study continued the comparison for six months. Despite good results, FDA encourages DAYVIGO to be placed under the controlled substances and such is currently being evaluated by the U.S. Drug Enforcement Administration (DEA) before being commercially available.

"We believe the approval of DAYVIGO is particularly exciting because it is the first FDA-approved medication to report safety data over a 12-month period along with sleep onset and sleep maintenance efficacy data over a six-month period in a pivotal clinical study," said Lynn Kramer, MD, Chief Clinical Officer, Neurology Business Group, Eisai Pharmaceutical. "We look forward to making this new therapeutic option available to the millions of patients who suffer with insomnia."

DAYVIGO was developed by the pharmaceutical drug company, Eisai.

"Insomnia disorder is a chronic condition that has a variety of potential negative impacts and long-term consequences for health and well-being,"2 said Russell Rosenberg, PhD, D.ABSM, a principal investigator in the DAYVIGO clinical studies and former Chairman of the Board of the National Sleep Foundation. "The clinical trials provide evidence that DAYVIGO may improve patients' ability to fall asleep and stay asleep."

In both studies, the most commonly reported side-effects that led to discontinuation was because somnolence and nightmares. In addition, the effects of DAYVIGO at the beginning of treatment were generally the same as the endpoint.

The drug was not associated with rebound insomnia following discontinuation or any withdrawal effects. However, DAYVIGO was associated with dose-dependent worsening effects on attention and memory compared to the placebo.

"DAYVIGO is an important addition to Eisai's rapidly growing neurology portfolio and underscores our leadership in neuroscience," said Ivan Cheung, Chairman and CEO, Eisai Inc. and Global President, Neurology Business Group, Eisai Co., Ltd. "Our commitment to patients and their families drives our relentless pursuit of innovative healthcare solutions."

Source: FDA

About the Author
  • Nouran earned her BS and MS in Biology at IUPUI and currently shares her love of science by teaching. She enjoys writing on various topics as well including science & medicine, global health, and conservation biology. She hopes through her writing she can make science more engaging and communicable to the general public.
You May Also Like
OCT 01, 2020
Drug Discovery & Development
HPV Vaccine Protects Against Cervical Cancer, Large Study Finds
OCT 01, 2020
HPV Vaccine Protects Against Cervical Cancer, Large Study Finds
It has been known for some time that the HPV vaccine protects against human papillomavirus infection, genital warts, and ...
OCT 16, 2020
Drug Discovery & Development
FDA Warns Against NSAIDs After Week 20 of Pregnancy
OCT 16, 2020
FDA Warns Against NSAIDs After Week 20 of Pregnancy
The US Food and Drug Administration (FDA) has warned against using nonsteroidal anti-inflammatory drugs (NSAIDs) from 20 ...
OCT 11, 2020
Drug Discovery & Development
Treating Connective Tissue Disorders
OCT 11, 2020
Treating Connective Tissue Disorders
Collaborative research efforts are geared to improving disease that affects connective tissues via innovative drug deliv ...
OCT 20, 2020
Drug Discovery & Development
The Power of Extracellular Vesicles
OCT 20, 2020
The Power of Extracellular Vesicles
What are extracellular vesicles (EVs)? They are tiny nanometer sized messengers that transport themselves between cells ...
NOV 23, 2020
Drug Discovery & Development
Therapeutically Active Ion-Channels
NOV 23, 2020
Therapeutically Active Ion-Channels
Therapeutically relevant ion channels have inspired researchers to look into drugs that can regulate their activity. Ion ...
DEC 01, 2020
Immunology
Scar-Free Healing Starts With Mobilizing the Immune System
DEC 01, 2020
Scar-Free Healing Starts With Mobilizing the Immune System
Thanks to a new hydrogel biomaterial developed by researchers at Duke University, we are one step closer to the holy gra ...
Loading Comments...